High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Eli Lilly just posted its fourth straight earnings beat and raised guidance again, but the real question is whether a next-generation obesity drug still sitting below Wall Street's radar could push the stock well past current targets.
For years, healthcare and semiconductor stocks weren’t particularly tied to each other. In other words, they increasingly go in opposite directions: when chips sell off, healthcare has tended to catch a bid. After years of underperformance, healthcare investors are enjoying a burst of momentum amid the recent nervousness around AI.
The stock is up just 8% this year and could prove to be an undervalued buy.
REGENXBIO (NASDAQ:RGNX) reported second-quarter 2026 progress across its late-stage gene-therapy pipeline, highlighting completed enrollment in its Duchenne muscular dystrophy confirmatory study, an agreed path to resubmit its Hunter syndrome therapy application, and the start of a pivotal diabetic
Regenxbio advances RGX-202 and RGX-121 programs while securing $208 million in new funding to support operations through late 2027.
Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.
AbbVie raises 2026 revenue guidance on Skyrizi, Rinvoq and neuroscience growth, while the Apogee deal trims EPS guidance and lifts R&D spending.
AbbVie Inc (ABBV) beats expectations with 10.2% revenue growth, raises full-year guidance, and showcases promising pipeline developments despite Humira's decline.
Moby summary of AbbVie Inc.'s Q2 2026 earnings call
AbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution
AbbVie (NYSE:ABBV) reported second-quarter 2026 results that exceeded its expectations, supported by double-digit growth in its immunology and neuroscience businesses, and raised its full-year revenue outlook by $300 million. Chairman and Chief Executive Officer Rob Michael said adjusted earnings p
Revenue of $16.99 billion and adjusted EPS of $3.65 both beat estimates
The drugmaker beat second-quarter estimates on strong immunology sales but lowered its full-year adjusted earnings outlook by 14 cents a share
AbbVie (ABBV) delivered earnings and revenue surprises of +0.28% and +1.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
AbbVie lowered its full-year adjusted earnings outlook to account for its acquisition of Apogee Therapeutics, as the company logged higher profit and revenue in the recent quarter.
AbbVie shares took a hit Friday after costs related to the drugmaker’s acquisition of Apogee Therapeutics forced a cut to its full-year profit outlook. Second-quarter revenue jumped 10% to nearly $17 billion, beating the $16.8 billion consensus estimate among analysts polled by FactSet. AbbVie posted adjusted earnings of $3.65 a share, narrowly ahead of Wall Street’s call for $3.60.
Investing.com -- AbbVie Inc. (NYSE: ABBV) reported second-quarter earnings before the open on Friday, missing profit expectations, although revenue beat the consensus estimate.
Find insight on Sanofi, Haleon, Cochlear and more in the latest Market Talks covering the health care sector.
Asking for a Trend Host Josh Lipton previews what investors should be on the lookout for on Friday, July 31, including earnings from energy giants Exxon (XOM), Chevron (CVX), and biopharma AbbVie (ABBV) as well as the latest read on consumer sentiment.
Asking for a Trend Host Josh Lipton previews what investors should be on the lookout for on Friday, August 1, including earnings from energy giants Exxon (XOM), Chevron (CVX), and biopharma AbbVie (ABBV) as well as the latest read on consumer sentiment.
Pharmaceutical company AbbVie (NYSE:ABBV) will be announcing earnings results this Friday before market hours. Here’s what to look for.
Today Earnings (a.m.): Mastercard, Hershey, KKR, Yum Brands, Cigna, Regeneron, Valero Energy, Norwegian Cruise Line, Hyatt Hotels, Bristol-Myers Squibb, Altria, International Paper, SiriusXM, Blue Owl Capital Earnings (p.
AbbVie(ABBV) reports second-quarter results on Friday, July 31, and the mood around the stock has changed. A few months ago, investors were restless. The two drugs carrying the company were doing fine, but everyone already knew that, and the market wanted a new reason to invest. Goldman Sachs went ...
AbbVie closed above the 230.47 buy point from a cup-with-handle base on June 23 and has climbed 15% from there. The previous day, the stock jumped more than 6% after AbbVie announced it agreed to acquire Apogee Therapeutics. The $10.9 billion deal would strengthen AbbVie's immunology pipeline.
A 2.8% Social Security raise barely covers a trip to the grocery store, so retirees are quietly rebuilding their paychecks around five dividend stocks with track records stretching back through every recession of the past two decades.
Strong biotech returns, major pharma acquisitions and new IPO filings are reshaping the 2026 U.S. listing market.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
